The wide gulf between stage III and stage IV colon cancer
Mené dans 340 centres hospitaliers européens sur 2 559 patients atteints d'un cancer du côlon de stade III, cet essai de phase III évalue l'efficacité, du point de vue de la survie sans maladie, et la toxicité de l'ajout de cetuximab à un protocole standard de chimiothérapie adjuvante (FOLFOX4)
The treatment of metastatic colorectal cancer has improved markedly during the past 15 years. With the development of irinotecan, oxaliplatin, anti-EGFR antibodies, and anti-VEGF treatment, patients with stage IV colon cancer live on average for 2 years after diagnosis, and 20% of patients can expect to live for 5 years or longer. However, of these recent additions to fluorouracil, only oxaliplatin has been useful in the adjuvant setting for patients with stage III colon cancer...
The Lancet Oncology , commentaire, 2013